Literature DB >> 19322208

Successful induction therapy with decitabine in refractory childhood acute lymphoblastic leukemia.

L Yánez, A Bermúdez, C Richard, E Bureo, A Iriondo.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19322208     DOI： 10.1038/leu.2009.58

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  12 in total

1.  Safety and clinical activity of 5-aza-2'-deoxycytidine (decitabine) with or without Hyper-CVAD in relapsed/refractory acute lymphocytic leukaemia.

Authors:  Christopher B Benton; Deborah A Thomas; Hui Yang; Farhad Ravandi; Michael Rytting; Susan O'Brien; Anna R Franklin; Gautam Borthakur; Samuel Dara; Monica Kwari; Sherry R Pierce; Elias Jabbour; Hagop Kantarjian; Guillermo Garcia-Manero
Journal:  Br J Haematol       Date:  2014-07-26       Impact factor: 6.998

2.  Durable remission with salvage decitabine and donor lymphocyte infusion (DLI) for relapsed early T-cell precursor ALL.

Authors:  F El Chaer; N Holtzman; E Binder; N C Porter; Z N Singh; M Koka; A P Rapoport; A Emadi
Journal:  Bone Marrow Transplant       Date:  2017-09-11       Impact factor: 5.483

Review 3.  Targeting paediatric acute lymphoblastic leukaemia: novel therapies currently in development.

Authors:  Alisa B Lee-Sherick; Rachel M A Linger; Lia Gore; Amy K Keating; Douglas K Graham
Journal:  Br J Haematol       Date:  2010-08-31       Impact factor: 6.998

4.  Immunotoxin resistance via reversible methylation of the DPH4 promoter is a unique survival strategy.

Authors:  Hui Wei; Laiman Xiang; Alan S Wayne; Oleg Chertov; David J FitzGerald; Tapan K Bera; Ira Pastan
Journal:  Proc Natl Acad Sci U S A       Date:  2012-04-16       Impact factor: 11.205

Review 5.  Pharmacotherapeutic advances in the treatment of acute lymphoblastic leukaemia in adults.

Authors:  Mark R Litzow
Journal:  Drugs       Date:  2011-03-05       Impact factor: 9.546

Review 6.  Relapsed or refractory pediatric acute lymphoblastic leukemia: current and emerging treatments.

Authors:  Alissa Martin; Elaine Morgan; Nobuko Hijiya
Journal:  Paediatr Drugs       Date:  2012-12-01       Impact factor: 3.022

7.  A therapeutic trial of decitabine and vorinostat in combination with chemotherapy for relapsed/refractory acute lymphoblastic leukemia.

Authors:  Michael J Burke; Jatinder K Lamba; Stanley Pounds; Xueyuan Cao; Yogita Ghodke-Puranik; Bruce R Lindgren; Brenda J Weigel; Michael R Verneris; Jeffrey S Miller
Journal:  Am J Hematol       Date:  2014-06-27       Impact factor: 10.047

Review 8.  Pediatric relapsed or refractory leukemia: new pharmacotherapeutic developments and future directions.

Authors:  Keith J August; Aru Narendran; Kathleen A Neville
Journal:  Drugs       Date:  2013-04       Impact factor: 9.546

9.  Genetic methylation and lymphoid malignancies: biomarkers of tumor progression and targeted therapy.

Authors:  Xia Zhao; Wei Zhang; Li Wang; Wei-Li Zhao
Journal:  Biomark Res       Date:  2013-08-14

10.  Chidamide and decitabine can synergistically induce apoptosis of Hodgkin lymphoma cells by up-regulating the expression of PU.1 and KLF4.

Authors:  Tao Jiang; Fujue Wang; Lianjie Hu; Xiaomin Cheng; Yuhuan Zheng; Ting Liu; Yongqian Jia
Journal:  Oncotarget       Date:  2017-09-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.